Protai grabs $ 8 million for AI-driven drug discovery platform


What you should know:

Of couse, based in Tel Aviv, Israel Powered by AI The drug-discovery startup today announced the emergence of Stealth, along with a $ 8 million round of seed funding co-led by Grove Ventures i Pitango HealthTech.

– Protai promotes the discovery of drugs with proteomics and artificial intelligence to unlock new layers of biological knowledge and fight complex diseases.

Proteomics-based platform for faster and more accurate drug discovery

Despite the significant contribution of genome-level information to drug R&D efforts, this information does not represent the functional layer of the cell that is reflected and dominated by proteins. This lack of functional understanding of the molecular mechanisms of a disease is one of the main shortcomings of the current process of drug discovery and development.

Founded by Eran Seger and Kirill Pevzner, Protai has built an AI-based end-to-end platform that comprehensively maps the course of a disease to a protein level, improving the ability to observe cell function, and, therefore, improving the way new drugs are discovered. . This effective approach allows Protai to increase the accuracy of drug discovery and improve the development process, substantially saving time and reducing R&D costs.

The company plans to use the funding to further develop Protai’s platform, accelerate its discovery programs and improve its partnerships with pharmaceutical companies.

Source link